Astrazeneca (AZN) Inventory Average (2009 - 2026)

Astrazeneca has reported Inventory Average for 18 years, with the latest figure at $6.8 billion in Q2 2026.

• On a quarterly basis, Inventory Average rose 9.32% year-over-year to $6.8 billion in Q2 2026; TTM through Jun 2026 was $6.8 billion, a 9.32% increase from a year earlier, with the FY2025 full-year figure at $5.9 billion, up 10.58% from the prior year.
• Inventory Average was $6.8 billion for Q2 2026 at Astrazeneca, up from $6.6 billion in the prior quarter.
• The five-year high for Inventory Average was $8.3 billion in Q1 2022, with the low at $4.8 billion in Q1 2023.
• Average Inventory Average over 5 years is $5.9 billion, with a median of $5.6 billion recorded in 2022.
• The largest YoY upside for Inventory Average was 100.04% in 2022 against a maximum downside of 49.89% in 2022.
• Over 5 years, Inventory Average stood at $4.9 billion in 2022, then rose by 9.6% to $5.4 billion in 2023, then rose by 2.18% to $5.5 billion in 2024, then rose by 20.09% to $6.6 billion in 2025, then grew by 2.68% to $6.8 billion in 2026.
• The last three Inventory Average figures came in at $6.8 billion (Q2 2026), $6.6 billion (Q1 2026), and $6.6 billion (Q4 2025), per Business Quant data.